Subjects n | 115 | 292 | 44 | 445 |
Male gender | 52 (45%) | 168 (58%) | 25 (57%) | 268 (60%) |
Age years | 50 (45–58) | 39 (33–48) | 52 (42–59) | 28 (22–39) |
Previous TB treatment | 24 (21%) | 79 (27%) | 6 (14%) | 96 (22%) |
Previously diagnosed diabetes | 83 (72.2%) | NA | 32 (72.7%) | NA |
Newly diagnosed diabetes | 32 (27.8%) | NA | 12 (27.3%) | NA |
HIV infection | 0 | 0 | 1 (2.3%) | 18 (4.0%) |
M. tuberculosis lineage |
East-Asian | 40 (34.8%) | 90 (30.8%) | 7 (15.9%) | 59 (13.3%) |
Euro-American | 69 (60.0%) | 178 (61.0%) | 37 (84.1%) | 386 (86.7%) |
Indo-Oceanic | 5 (4.3%) | 24 (28.2%) | 0 | 0 |
M. bovis | 1 (0.9%) | 0 | 0 | 0 |
Any drug resistance | 21 (18.3%) | 44 (15.1%) | 17 (38.6%) | 88 (19.8%) |
Isoniazid resistance | | | | |
katG | 8 (7.0%) | 19 (6.5%) | 6 (13.6%) | 48 (10.8%) |
Rv1482c-fabG1 | 3 (2.6%) | 10 (3.4%) | 8 (18.2%)** | 23 (5.2%)** |
ahpC | 0 | 0 | 1 (2.3%) | 0 |
Rifampicin resistance | | | | |
rpoB | 9 (7.8%) | 10 (3.4%) | 7 (15.9%) | 42 (9.4%) |
Ethambutol resistance | | | | |
embB | 3 (2.6%) | 6 (2.1%) | 5 (11.4%) | 30 (6.7%) |
embC-embA | 0 | 0 | 1 (2.3%) | 6 (1.3%) |
embR | 0 | 1 (0.3%) | 0 | 0 |
Streptomycin resistance | | | | |
rpsL | 4 (3.5%) | 5 (1.7%) | 1 (2.3%) | 16 (3.6%) |
rrs | 1 (0.9%) | 2 (0.7%) | 0 | 5 (1.1%) |
Pyrazinamide resistance | | | | |
pncA | 7 (6.1%) | 14 (4.8%) | 3 (6.8%) | 22 (4.9%) |
Ethionamide resistance | | | | |
Rv1482c-fabG1 | 3 (2.6%) | 10 (3.4%) | 8 (18.2%)** | 22 (4.9%)** |
ethA | 0 | 0 | 0 | 1 (0.2%) |
Fluoroquinolone resistance | | | | |
gyrA | 3 (2.6%) | 3 (1.0%) | 4 (9.1%)* | 7 (1.6%)* |
gyrB | 0 | 0 | 0 | 2 (0.4%) |
Amikacin resistance | | | | |
rrs | 0 | 0 | 0 | 5 (1.1%) |
Capreomycin resistance | | | | |
tlyA | 0 | 1 (0.3%) | 0 | 7 (1.6%) |
rrs | 0 | 0 | 0 | 5 (1.1%) |
Kanamycin resistance | | | | |
eis-Rv2417c | 1 (0.9%) | 1 (0.3%) | 1 (2.3%) | 1 (0.2%) |
rrs | 0 | 0 | 0 | 5 (1.1%) |
Para-aminosalicylic acid resistance | | | | |
folC | 0 | 2 (0.7%) | 1 (2.3%) | 2 (0.4%) |
thyA | 0 | 0 | 0 | 1 (0.2%) |